INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Option exerciseVerified data

Lennon David James reported WHWK

Director, CHIEF EXECUTIVE OFFICER · Whitehawk Therapeutics, Inc. · Whitehawk Therapeutics, Inc. — Restricted Stock Units

Side
M
Value
—
Shares
16.3K
Price
—
Executed
Mar 1, 2026
Disclosed
Mar 10, 2026
Disclosure timeline9 days from execution to publication · legal deadline 2 business days
Mar 1 executedMar 10, 2026 disclosed

WHWK · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
31/ 100 · ELEVATED
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

No reported dollar value · 100.0% of prior position

  • Filing timing+10 / 15

    Disclosed 7 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · WHWK

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    91.6K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    GM
    Giacobello Scott M.CHIEF FINANCIAL OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    118.5K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    GM
    Giacobello Scott M.CHIEF FINANCIAL OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    118.5K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DM
    Dugan MargaretChief Medical Officer
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    81.3K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    2
    LJ
    Lennon David JamesDirector, CHIEF EXECUTIVE OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    194.0K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    2
    LJ
    Lennon David JamesDirector, CHIEF EXECUTIVE OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    194.0K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DD
    Dornan DavidChief Scientific Officer
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    85.9K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DD
    Dornan DavidChief Scientific Officer
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    85.9K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    5
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    91.6K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    DM
    Dugan MargaretChief Medical Officer
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    81.3K sh
    		Sep 15, 2026Sep 15, 2026
    traded Sep 15, 2026
    		+0dSEC FORM 4

    Evidence

    9
    IK
    Iyengar Vijay KDirector
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    76.1K sh
    		Sep 9, 2026Sep 11, 2026
    traded Sep 9, 2026
    		+2dSEC FORM 4

    Evidence

    9
    ZB
    Zhao BaitengDirector
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    38.0K sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    9
    DN
    Desai NeilDirector
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A—
    38.0K sh
    		Jun 12, 2026Jun 15, 2026
    traded Jun 12, 2026
    		+3dSEC FORM 4

    Evidence

    9
    LJ
    Lennon David JamesDirector, CHIEF EXECUTIVE OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Grant or award
    		A$200K
    51.0K sh
    		May 14, 2026May 18, 2026
    traded May 14, 2026
    		+4dSEC FORM 4

    Evidence

    29
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$91K
    26.4K sh
    		Apr 13, 2026Apr 15, 2026
    traded Apr 13, 2026
    		+2dSEC FORM 4

    Evidence

    32
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$337K
    92.5K sh
    		Apr 14, 2026Apr 15, 2026
    traded Apr 14, 2026
    		+1dSEC FORM 4

    Evidence

    22
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$23K
    6,596 sh
    		Apr 10, 2026Apr 13, 2026
    traded Apr 10, 2026
    		+3dSEC FORM 4

    Evidence

    33
    BB
    Ball BryanSee remarks
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$179K
    50.0K sh
    		Apr 9, 2026Apr 13, 2026
    traded Apr 9, 2026
    		+4dSEC FORM 4

    Evidence

    22
    LJ
    Lennon David JamesDirector, CHIEF EXECUTIVE OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$49K
    14.5K sh
    		Apr 9, 2026Apr 10, 2026
    traded Apr 9, 2026
    		+1dSEC FORM 4

    Evidence

    32
    LJ
    Lennon David JamesDirector, CHIEF EXECUTIVE OFFICER
    WHWKWhitehawk Therapeutics, Inc.
    Open-market sale
    		SELL$323K
    94.1K sh
    		Apr 7, 2026Apr 8, 2026
    traded Apr 7, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001995275-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 1, 2026
    Published
    Mar 10, 2026
    Ingested by INSIDER
    Nov 5, 04:12 UTC
    Last re-read
    Nov 5, 04:12 UTC

    Extracted facts

    Filer
    Lennon David James
    Role
    Director, CHIEF EXECUTIVE OFFICER
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Whitehawk Therapeutics, Inc. — Restricted Stock Units
    Ticker
    WHWK
    Shares
    16.3K
    Price per share
    $0
    Execution date (reported)
    Mar 1, 2026
    Owned after transaction
    32.5K shares
    Days from execution to publication
    9

    What this establishes

    Lennon David James filed this Form 4 reporting a option exercise of WHWK on Mar 1, 2026. It became public on Mar 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CHIEF EXECUTIVE OFFICER
    Lennon David Jamescik:0001995275
    Issuer
    Whitehawk Therapeutics, Inc.cik:0001422142

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.